Vnitr Lek 2006, 52(9):827-829
Britové odsoudili užití beta-blokátorů u hypertenze
- 1 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
- 2 I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
Received: August 7, 2006; Published: September 1, 2006 Show citation
References
- Cífková R, Horký K, Widimský J sr et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2004; 50: 709-722.
Go to PubMed...
- Dahlof B, Devereux RB, Kjeldsen SE (for the LIFE investigators). Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
Go to original source...
Go to PubMed...
- Lindholm LH, Samuelsson O. What are the odds at ASCOT today. Lancet 2003; 361: 1144-1145.
Go to original source...
Go to PubMed...
- Poulter NR (for the ASCOT investigators). Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913.
Go to original source...
Go to PubMed...
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
Go to original source...
Go to PubMed...
- Zanchetti A for the guidelines committee 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hyperten 2003; 21: 1011-1023.
Go to original source...
Go to PubMed...